WHO Pharmaceuticals Newsletter (No.2, 2014)

OMS, 30 de mayo 2014

Regulatory Matters

Aliskiren, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers ........................................................................................ ….............................4

Azathioprine and mercaptopurine .................................. ............................... 4

Cetuximab ..................................................................... ................................ 4

Combined hormonal contraceptives ................ ........... ................................ .5

Diacerein-containing medicines .......................... .. ....................................... 5

Doripenem ........................................................... ..........................................5

Lithium ..................................................................... .................................. ...5

Methysergide-containing medicines ........................... ................................... 6

Orlistat .......................................................................................................... 6

Quetiapine ................................................................... ................................. .7

Strontium ranelate ...........................................................................................7

Safety of medicines

Saxagliptin ...................................................................... ..............................8

St John’s wort and hormonal contraceptives, including implants .. ...............8

Testosterone Products ....................................................................................8

Signal

Combined Citalopram and Ramipril treatment - Hyponatraemia ...... ............ 10

Combined Ibuprofen and Metamizole treatment - Acute renal failure .......... 13

Tocilizumab – Psoriasis and Aggravated psoriasis ........................................ 16

Vemurafenib and Pancreatitis ........................................................................ 23

dsiponible en

http://www.who.int/entity/medicines/publications/NewsletterNo2_2013EC.pdf